Benzhexol HCl - CAS 52-49-3
Catalog number: 52-49-3
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C20H32ClNO
Molecular Weight:
337.94
COA:
Inquire
Targets:
mAChR
Description:
Benzhexol HCl is an anticholinergic tertiary amine used to treat parkinsonism and the extrapyramidal side effects of anti-psychotic drugs.
Publictions citing BOC Sciences Products
  • >> More
Purity:
≥98%
Appearance:
White Solid
Synonyms:
Trihexyphenidyl Hydrochloride; 1-cyclohexyl-1-phenyl-3-piperidin-1-ylpropan-1-ol;hydrochloride;Trihexyphenidylhydrochloride;Benzhexolhydrochloride;Artane;52-49-3
Solubility:
Soluble in DMSO
Storage:
Store at -20 °C
MSDS:
Inquire
Application:
Anticholinergic tertiary amine
Quality Standard:
Enterprise Standard/USP/EP
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly
Quantity:
Grams-Kilos
Boiling Point:
447.9ºC at 760mmHg
Melting Point:
>251 °C
InChIKey:
QDWJJTJNXAKQKD-UHFFFAOYSA-N
InChI:
1S/C20H31NO.ClH/c22-20(18-10-4-1-5-11-18,19-12-6-2-7-13-19)14-17-21-15-8-3-9-16-21;/h1,4-5,10-11,19,22H,2-3,6-9,12-17H2;1H
Canonical SMILES:
C1CCC(CC1)C(CCN2CCCCC2)(C3=CC=CC=C3)O.Cl
1.Carriers for skin delivery of trihexyphenidyl HCl: ethosomes vs. liposomes.
Dayan N1, Touitou E. Biomaterials. 2000 Sep;21(18):1879-85.
The purpose of this work was to characterize a novel ethosomal carrier containing trihexyphenidyl HCl (THP) and to investigate the delivery of THP from ethosomes versus classic liposomes. THP-ethosomal systems were shown by electron microscopy to contain small, phospholipid vesicles. As the THP concentration was increased from 0 to 3%, the size of the vesicles decreased from 154 to 90 nm. This is most likely due to the surface activity of THP (critical micelle concentration of 5.9 mg/ml), as measured in this work. In addition, the ethosome zeta potential value increased as a function of THP concentration, from -4.5 to +10.4 when the THP concentration was increased from 0 to 3%. In contrast, THP liposomes were much larger and their charge was not affected by THP. When compared with standard liposomes, ethosomes had a higher entrapment capacity and a greater ability to deliver entrapped fluorescent probe to the deeper layers of skin. The flux of THP through nude mouse skin from THP ethosomes (0.
2.[A-56-year-old woman with parkinsonism, whose mother had Parkinson's disease].
Shimo Y1, Takanashi M, Ohta S, Terashima K, Mori H, Shirai T, Miwa H, Mizuno Y. No To Shinkei. 2001 May;53(5):495-505.
We report a 56-year-old woman with progressive gait disturbance. Her mother had Parkinson's disease with onset at age 70. She died at age 74 and the post-mortem examination confirmed the diagnosis of Lewy body positive Parkinson's disease. The patient was well until the age of 50(1995) when she noted an onset of resting tremor and difficulty of gait. She also developed delusional ideation and was admitted to a psychiatric service of another hospital, where a major tranquilizer was given. The delusion disappeared but she developed marked rigidity. The major tranquilizer was discontinued and an anticholinergic and amantadine HCl were given. She showed marked improvement to Hoehn and Yahr stage II and was discharged. In 1995, when she was 52 years of the age, she developed delusion again and a major tranquilizer was given. She developed marked parkinsonism again and became Hoehn and Yahr stage V. The major tranquilizer was discontinued and she was treated with levodopa/carbidopa, trihexyphenidyl, bromocriptine, and dops.
3.[A case of choreoathetoid movements induced by anticholinergic drugs, trihexyphenidyl HCl and dosulepin Matsumoto K1, Nogaki H, Morimatsu M. Nihon Ronen Igakkai Zasshi. 1992 Sep;29(9):686-9.
We report a 72-year-old woman who showed marked orolingual dyskinesia and choreoathetoid movements of the neck, with rolling and nodding of the head. She had been treated for postural tremor and other complaints with multiple drugs, including trihexyphenidyl HCl (THP) 6 mg/day for about two years. Moreover, two months before admission to our hospital, a doctor added tricyclic antidepressant, dosulepin HCl (DL) because of her state of anxiety. Two weeks following DL administration, the persistent dyskinesia described above appeared. Suspecting the dyskinesia to be induced by anticholinergics, we withdrew THP, which decreased the intensity of the dyskinesia. Then, when DL was ceased the dyskinesia almost completely disappeared, slightly recurring only during calculating, when excited or writing. In order to confirm that anticholinergics were the cause of the dyskinesia, we administered THP 6 mg/day again. In a few days the same dyskinesia reappeared, disappearing following THP withdrawal.
4.Effects of anticholinergic agents on patients with tardive dyskinesia and concomitant drug-induced parkinsonism.
Wirshing WC1, Freidenberg DL, Cummings JL, Bartzokis G. J Clin Psychopharmacol. 1989 Dec;9(6):407-11.
Twenty-five percent of 80 consecutive patients who met research criteria for persistent tardive dyskinesia (TD) were found to have an energy peak in the parkinsonian tremor band (3-6 Hz) of the frequency spectrum of their machine-measured resting hand movements in addition to the abnormalities consistent with TD (increased energy in the 0.5-3 Hz frequency spectrum). Twelve of these patients were studied again in double-blind fashion 2 hours after receiving a placebo and again 2 hours after a single 4 mg dose of trihexyphenidyl hydrochloride (HCl). Compared with the placebo condition, the trihexyphenidyl HCl markedly diminished the measured energy in the 4 Hz band and had no effect or slightly decreased the energy at all other points on the frequency spectrum. Simultaneous Abnormal Involuntary Movement Scale ratings revealed no change in the dyskinetic movements between the conditions; there was a significant subjective improvement reported by the patients following the trihexyphenidyl HCl administration.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related mAChR Products


CAS 590-63-6 Bethanechol Chloride

Bethanechol Chloride
(CAS: 590-63-6)

A selective muscarinic receptor stimulant, used to treat cerebral palsy.

GYKI-46903 HCl
(CAS: 142999-59-5)

GYKI-46903 is a Muscarinic M3 receptor and Serotonin 3 receptor antagonist. In displacement studies, the pIC50 values of GYKI-46903 against [3H]granisetron bind...

CAS 76-90-4 Mepenzolate Bromide

Mepenzolate Bromide
(CAS: 76-90-4)

Mepenzolate Bromide is a muscarinic antagonist used to treat gastrointestinal disorders, and decreases the severity of elastase-induced airspace enlargement and...

CAS 107220-28-0 Cevimeline hydrochloride

Cevimeline hydrochloride
(CAS: 107220-28-0)

Cevimeline hydrochloride is a selective M1 receptor agonist.

CAS 10049-83-9 Pyrithioxin dihydrochloride

Pyrithioxin dihydrochloride
(CAS: 10049-83-9)

Pyrithioxin dihydrochloride, a pyridine thiol derivative, is a nootropic which could be used in the treatment of sequelae of brain trauma, encephalitis and meni...

CAS 119391-56-9 mAChR-IN-1

mAChR-IN-1
(CAS: 119391-56-9)

mAChR-IN-1 is a potent muscarinic cholinergic receptor(mAChR) antagonist with IC50 of 17 nM.

CAS 26095-59-0 Otilonium Bromide

Otilonium Bromide
(CAS: 26095-59-0)

Otilonium Bromide is an antimuscarinic used as a spasmolytic agent.

CAS 155-41-9 Methscopolamine

Methscopolamine
(CAS: 155-41-9)

Methscopolamine is a muscarinic acetylcholine receptor blocker.

CAS 171722-81-9 YM-46303

YM-46303
(CAS: 171722-81-9)

YM-46303 is an mAChR antagonist which had a binding affinity of 0.39 nM to M3-receptors. YM-46303 exhibits the highest affinities for M1 and M3 receptors. YM-46...

CAS 133099-04-4 Darifenacin

Darifenacin
(CAS: 133099-04-4)

Darifenacin hydrobromide is an antispasmodic muscarinic antagonist, selective for blocking the M3 muscarinic acetylcholine receptor, which is primarily responsi...

CAS 54-30-8 Camylofine dihydrochloride

Camylofine dihydrochloride
(CAS: 54-30-8)

Camylofine dihydrochloride is an antimuscarinic used as a smooth muscle relaxant.

CAS 136310-93-5 Tiotropium bromide

Tiotropium bromide
(CAS: 136310-93-5)

Tiotropium Bromide, an azoniatricyclo derivative, is a mAChR antagonist that could be used as bronchodilation agent and smooth muscle relaxant.

CAS 6989-98-6 Tubocurarine hydrochloride pentahydrate

Tubocurarine hydrochloride pentahydrate
(CAS: 6989-98-6)

Tubocurarine is a toxic alkaloid. It is an acetylcholine receptor (AChR)-blocking agent. Tubocurarine is now rarely used as an adjunct for clinical anesthesia b...

CAS 180468-39-7 Solifenacin hydrochloride

Solifenacin hydrochloride
(CAS: 180468-39-7)

Muscarinic M3 receptor antagoinst. Used in treatment of urinary incontinence.

CAS 50-34-0 Propantheline Bromide

Propantheline Bromide
(CAS: 50-34-0)

Propantheline Bromide is an antimuscarinic agent used as an antispasmodic for the treatment of ulcers.

CAS 84504-69-8 Irsogladine maleate

Irsogladine maleate
(CAS: 84504-69-8)

Irsogladine is a PDE4 inhibitor and muscarinic acetylcholine receptor binder. It inhibits bFGF-induced angiogenesis in wild-type, tPA-knockout, and uPA-knockout...

CAS 62-97-5 Diphemanil Methylsulfate

Diphemanil Methylsulfate
(CAS: 62-97-5)

Diphemanil Methylsulfate is a quaternary ammonium anticholinergic.It binds muscarinic acetycholine receptors (mAchR).

CAS 1004312-94-0 M3 receptor antagonist 1

M3 receptor antagonist 1
(CAS: 1004312-94-0)

An antagonist of muscarinic M3-receptor

CAS 55869-99-3 Anisodamine

Anisodamine
(CAS: 55869-99-3)

Anisodamine is a alkaloid shown to be a weak antagonist of α1-adrenoceptors, blocking WB-4101 and clonidine by binding in brain membrane preparations.

CAS 1098-97-1 Pyrithioxin

Pyrithioxin
(CAS: 1098-97-1)

Pyrithioxin, a pyridine thiol derivatives, could be used in the treatment of traumatic brain injury sequelae and some sorts of cerebral infarct patients with He...

Chemical Structure

CAS 52-49-3 Benzhexol HCl

Quick Inquiry

Verification code

Featured Items